Origin of Semax: folklore door, documented room

Search engines still surface nicknames like “KGB peptide,” “KGB brain spray,” and “Limitless peptide”. Those phrases are sticky. This page treats them as a door - the curiosity that brings people in - then walks you into a trustworthy room built from peer-reviewed and primary research history.

Educational only. Not medical advice. Semax Hub does not sell Semax.

The sticky door: “KGB peptide,” “KGB brain spray,” and “Limitless peptide”

What those nicknames are

Online, Semax is sometimes marketed or memed as a Cold War intelligence “brain spray.” The labels travel well: short, dramatic, easy to share. They are best understood as folklore / search nicknames, not as titles that appear on Institute of Molecular Genetics papers or Russian drug registrations.

Some people call Semax the “Limitless peptide” after the movie drug. That’s a nickname, not a scientific claim. The film’s NZT-48 was fictional; this is not a claim that Semax is NZT-48 or that it delivers movie-level enhancement.

What they are not

Folklore vs documented history

• Unconfirmed as an operational KGB field drug origin story in peer-reviewed literature.
• Not how Institute of Molecular Genetics (IMG) authors describe the molecule in design reviews.
• Not a substitute for the chemistry story: an adrenocorticotropic hormone (ACTH) fragment became Semax (MEHFPGP).
• Vendor “secret ops” timelines that lack archival or peer-reviewed citations should be treated as secondary myth, not primary history.

Plausible Soviet-era interest in stress, cognition, and extreme-environment performance (including aerospace / military research culture) is a different claim from “the KGB invented and deployed Semax as an ops tool.” This page keeps those layers separate.

If you only came for the nickname: the rest of this page is the actual origin trail we can source.

The trustworthy room: Institute of Molecular Genetics, early 1980s

Where the documented story starts

Peer-reviewed summaries from researchers at the Institute of Molecular Genetics (IMG) of the Russian (formerly Soviet) Academy of Sciences, writing with Nikolay F. Myasoedov and colleagues, place Semax in a regulatory-peptide program associated with Igor P. Ashmarin and Myasoedov’s teams.

Timeline that holds up in that literature:

Collaborators frequently include Moscow State University physiology groups and later neurology / imaging teams. Commercial Russian nasal products have been associated with Peptogen (Innovation Research and Production Center) in Moscow - manufacturing identity, not the discovery claim.

Strongest single overview for English readers: Kolomin et al., Neuroscience & Medicine, 2013 (IMG RAS authors including Myasoedov). DOI: 10.4236/nm.2013.44035

Design memoir in the primary Russian literature: Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, et al., Zhurnal vysshei nervnoi deiatel'nosti, 1997: “15 years experience in its design and study.” PMID: 9173745

From ACTH fragment to MEHFPGP

Why ACTH(4–10)?

By the 1960s–1970s, peptide physiologists had noticed that short pieces of ACTH could affect learning and behavior in animals even when adrenal steroid effects were set aside. The fragment ACTH(4–10) was a leading prototype for “central nervous system (CNS) message without full endocrine punch” - but natural fragments were short-lived (often discussed as lasting only tens of minutes).

The Pro–Gly–Pro move

IMG/Ashmarin–Myasoedov teams systematically modified the C-terminal region. Replacing the natural C-terminal tripeptide with Pro–Gly–Pro (PGP) produced an analog whose behavioral activity in animals lasted many hours (reviews often cite on the order of 20–24 hours vs minutes for the natural fragment), while remaining non-corticotropic and without the melanocyte-stimulating hormonal profile of related peptides.

The winning sequence:

H–Met–Glu–His–Phe–Pro–Gly–Pro–OH (MEHFPGP)

That molecule was named Semax. Early peer-reviewed English-language enzymology work already treats “semax” as the synthetic ACTH(4–10) analog under study (e.g., Potaman et al., BBRC, 1991).

Plain language: Keep the brain-interesting ACTH message. Add a proline-rich tail so enzymes don’t erase it immediately. Drop the cortisol-raising job. That is the documented design logic - not a spy-movie plot device.

Brain growth-factor pathway follow-ons (BDNF/TrkB, monoamines, gene networks) are covered on How Semax works. Companion peptide Selank (tuftsin + PGP) came from the same design school: Semax vs Selank.

Aerospace / military stress–cognition context: plausible, not “confirmed KGB ops”

Soviet and later Russian science culture invested heavily in human performance under extreme load: hypoxia, fatigue, high cognitive demand, aerospace and defense-adjacent physiology. Semax reviews and secondary histories often mention interest in adaptability under extreme conditions in healthy persons alongside clinical neurology aims.

That background makes a plausible research context for a stress–cognition peptide program:

• national labs working on regulatory peptides
• interest in hypoxia resistance and workload (early Ashmarin/Kaplan-era themes appear in Russian physiology journals)
• a pathway from institute chemistry → ministry health evaluation → pharmacy product

What we do not claim here:

Unconfirmed: keep this distinction clear

A confirmed KGB operational origin - secret intelligence service invention, field deployment as a spy “brain spray,” or declassified ops doctrine naming Semax - is not established in the peer-reviewed trail we cite. Commercial history pages that assert Ministry-of-Defense “briefs” without primary archival documents remain secondary / unverified.

Sticky door ≠ trustworthy room. Folklore explained the clickbait; IMG + ACTH + PGP explain the molecule.

Path to Russian clinical registration and Vital Drugs context

From lab candidate to medicine

Kolomin et al. (2013) summarize the arc: after animal nootropic and safety framing, Semax entered Russian clinical development as nasal preparations (commonly discussed 0.1% general/nootropic framing and a higher-concentration 1% form oriented to heavier cerebrovascular use). By the mid-1990s it was in clinical practice; Ashmarin’s 1997 paper looks back on roughly fifteen years of design and study. Stroke-oriented neurology series (e.g., Gusev / Skvortsova collaborations) became a major clinical literature thread.

Registration

Modern Russian prescribing materials commonly cite registration such as ЛС-002553 (Semax nasal drops 0.1%, dated 30 December 2011 in current label packages), prescription-only release, Anatomical Therapeutic Chemical (ATC) N06BX (other psychostimulants and nootropics). Manufacturer materials also reference related registration numbers. Always treat registry numbers as checkable against the current ГРЛС state drug list.

Vital and Essential Drugs (ЖНВЛП)

Secondary sources (including encyclopedic summaries citing WHO-archived Russian list materials) state Semax appears on the list associated with Government Order № 2199-р of 7 December 2011 (list for 2012). That is national essential-medicines policy context - price/priority regulation - not U.S. Food and Drug Administration (FDA) / European Medicines Agency (EMA) approval, and not proof by contemporary Western Phase III standards.

Full regulatory split (Russia vs West): Regulatory status. Evidence quality map: Evidence.

“Sticky door, trustworthy room”: the structure we intend

Curiosity gets you through the door. Sources keep the room honest.

Uncertainty flags

1. Exact day-by-day lab notebooks from the early 1980s are not what most English readers can audit; we rely on later IMG-authored reviews and contemporary papers.
2. “Extreme conditions / healthy persons” language in reviews is broader than a documented single military protocol number.
3. Commercial timelines (e.g., “research started 1982; approved 1996”) appear on manufacturer-adjacent pages - useful as orientation, weaker than peer-reviewed design histories unless independently corroborated.
4. Essential-drugs lists update; a 2011–2012 snapshot may not match today’s pharmacy or reimbursement reality.
5. SCIRP / regional open journals vary in editorial culture; Kolomin 2013 is still the most convenient IMG-authored English synthesis, but cross-check claims against PubMed-indexed clinical and mechanistic papers when stakes are high.

Sources

1. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine. 2013;4:223–252. https://doi.org/10.4236/nm.2013.44035: primary cornerstone for this page: late-1970s start, PGP analog selection, MEHFPGP naming, non-corticotropic profile, Russian clinical framing.
2. Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420–430. PMID: 9173745.
3. Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochem Biophys Res Commun. 1991;176(2):741–746. doi:10.1016/S0006-291X(05)80247-5 · PMID: 1851003: early peer-reviewed English description era.
4. Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115–123.: early human volunteer/EEG-era report (historical; small by modern standards).
5. Dolotov OV, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108 · PMID: 16996037: optional mechanistic landmark from overlapping Russian groups (not an origin primary, but anchors the scientific lineage).
6. Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia… BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228: IMG/MSU ischemia transcriptomics lineage.
7. Official Russian prescribing information: Semax 0.1% nasal drops, registration ЛС-002553 (30.12.2011). Package insert PDF.
8. Russian Government Order № 2199-р (7 Dec 2011) / Vital & Essential Drugs list for 2012: see Minzdrav document page; encyclopedic secondary summary: Wikipedia: Semax (verify list membership against primary archives when currency matters).

Deliberately not used as primary history: anonymous vendor blogs, “secret KGB formula” marketing pages, and uncited ops chronologies.

Related hub pages

• What is Semax?: newcomer definition
• How Semax works: mechanisms + origin accuracy table
• Evidence map
• Safety & FAQs
• Regulatory
• Semax vs Selank